26816-1-AP

antibody from Proteintech Group

Targeting: CDK12 CRK7, CRKR, CRKRS, KIAA0904

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Data presented on provider website)

Antibody Data

Product number

26816-1-AP

Provider

Proteintech Group

Product name

CDK12/CRKRS antibody

Antibody type

Polyclonal

Description

KD/KO validated CDK12/CRKRS antibody (Cat. #26816-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IF, WB, ELISA.

Reactivity

Human

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

20ul, 150ul

References

Submitted references

Targeting CDK12 rescues C/EBPβ-mediated platinum and PARP inhibitor resistance in ovarian cancer.

Tan J, Dong W, Wang D, Tu A, Wang Z, Wu X, Zhang F, Zhu Y, Ren L, Ai Y, Feng Y, Zhang J
Cellular signalling 2026 Mar;139:112328

---

Dual Modes of Gene Regulation by CDK12.

Wang Y, Baluapuri A, Manokaran C, Ni J, Jiang T, Janssens RC, Marteijn JA, Adelman K, Zhao J, Roberts TM
bioRxiv : the preprint server for biology 2025 Sep 23;

---

CDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical models.

Bao Y, Chang Y, Tien JC, Cruz G, Yang F, Mannan R, Mahapatra S, Paturu R, Cao X, Su F, Wang R, Zhang Y, Gondal M, Choi JE, Gurkan JK, Miner SJ, Robinson DR, Wu YM, Zhou L, Wang Z, Kryczek I, Wang X, Cieslik M, Qiao Y, Tsodikov A, Zou W, Ding K, Chinnaiyan AM
The Journal of clinical investigation 2025 Sep 16;135(18)

---

Novel E-F ring derivatives of aconitine scaffold as potent Hsp90 inhibitors for the treatment of colorectal cancer.

Zhang Y, Wang YP, Guo S, Li TT, Wang QY, Zhang X, Zheng YM, Wen YQ, Meng FH, Zhang TJ
European journal of medicinal chemistry 2025 Oct 15;296:117895

---

Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma.

Tien JC, Zhai Y, Wu R, Zhang Y, Chang Y, Cheng Y, Todd AJ, Wheeler CE, Li S, Mannan R, Cheng C, Magnuson B, Cruz G, Cao Y, Mahapatra S, Stolfi C, Cao X, Su F, Wang R, Yang J, Zhou L, Qiao Y, Xiao L, Cieslik M, Wang X, Wang Z, Chou J, Fearon ER, Ding K, Cho KR, Chinnaiyan AM
Proceedings of the National Academy of Sciences of the United States of America 2025 Jun 17;122(24):e2426909122

---

Identification of a Potent and Selective CDK9 Degrader as a Targeted Therapeutic Option for the Treatment of Small-Cell Lung Cancer.

Wang Y, Wang M, Ma L, Zhang Y, Jiao Y, Zhang S, Yang Y, Li J, Wei M, Cao S, Zhang K, Liu S, Yang G
Journal of medicinal chemistry 2025 Feb 13;68(3):2528-2550

---

CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13.

Tien JC, Luo J, Chang Y, Zhang Y, Cheng Y, Wang X, Yang J, Mannan R, Mahapatra S, Shah P, Wang XM, Todd AJ, Eyunni S, Cheng C, Rebernick RJ, Xiao L, Bao Y, Neiswender J, Brough R, Pettitt SJ, Cao X, Miner SJ, Zhou L, Wu YM, Labanca E, Wang Y, Parolia A, Cieslik M, Robinson DR, Wang Z, Feng FY, Chou J, Lord CJ, Ding K, Chinnaiyan AM
Cell reports. Medicine 2024 Oct 15;5(10):101758

---

Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition.

Chang Y, Wang X, Yang J, Tien JC, Mannan R, Cruz G, Zhang Y, Vo JN, Magnuson B, Mahapatra S, Cho H, Dhanasekaran SM, Wang C, Wang Z, Zhou L, Zhou K, Zhou Y, Zhang P, Huang W, Xiao L, Liu WR, Hamadeh R, Su F, Wang R, Miner SJ, Cao X, Cheng Y, Mehra R, Ding K, Chinnaiyan AM
Cell reports. Medicine 2024 Oct 15;5(10):101752

---

Interaction of CDK12 with NXF1 is a new node for the linking mechanism between transcription and transportation of mRNA.

Ebara S, Yoshida M, Yamakawa H, Shimokawa K, Inoue Y, Tauchi H, Morishita D
Biochemical and biophysical research communications 2024 Nov 26;735:150608

---

Identifying human pre-mRNA cleavage and polyadenylation factors by genome-wide CRISPR screens using a dual fluorescence readthrough reporter.

Ni Z, Ahmed N, Nabeel-Shah S, Guo X, Pu S, Song J, Marcon E, Burke GL, Tong AHY, Chan K, Ha KCH, Blencowe BJ, Moffat J, Greenblatt JF
Nucleic acids research 2024 May 8;52(8):4483-4501

---

THOC5 complexes with DDX5, DDX17, and CDK12 to regulate R loop structures and transcription elongation rate.

Polenkowski M, Allister AB, Burbano de Lara S, Pierce A, Geary B, El Bounkari O, Wiehlmann L, Hoffmann A, Whetton AD, Tamura T, Tran DDH
iScience 2023 Jan 20;26(1):105784

---

JWA suppresses proliferation in trastuzumab-resistant breast cancer by downregulating CDK12.

Liang Y, Qian C, Xie Y, Huang X, Chen J, Ren Y, Fu Z, Li Y, Zeng T, Yang F, Zhou J, Li W, Yin Y, Wang C
Cell death discovery 2021 Oct 22;7(1):306

---

CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.

Li H, Wang J, Yi Z, Li C, Wang H, Zhang J, Wang T, Nan P, Lin F, Xu D, Qian H, Ma F
European journal of cancer (Oxford, England : 1990) 2021 Mar;145:92-108

---

Expression pattern of CDK12 protein in gastric cancer and its positive correlation with CD8(+) cell density and CCL12 expression.

Ji J, Zhou C, Wu J, Cai Q, Shi M, Zhang H, Yu Y, Zhu Z, Zhang J
International journal of medical sciences 2019;16(8):1142-1148